WO2005001048A3 - Preparation and application of anti-tumor bifunctional fusion proteins - Google Patents

Preparation and application of anti-tumor bifunctional fusion proteins Download PDF

Info

Publication number
WO2005001048A3
WO2005001048A3 PCT/US2004/017765 US2004017765W WO2005001048A3 WO 2005001048 A3 WO2005001048 A3 WO 2005001048A3 US 2004017765 W US2004017765 W US 2004017765W WO 2005001048 A3 WO2005001048 A3 WO 2005001048A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
application
fusion proteins
bifunctional fusion
tumor
Prior art date
Application number
PCT/US2004/017765
Other languages
French (fr)
Other versions
WO2005001048A2 (en
Inventor
Jing Ma
Yajun Guo
Original Assignee
Oncomax Acquisition Corp
Jing Ma
Yajun Guo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200310119930 external-priority patent/CN1297567C/en
Priority claimed from US10/723,003 external-priority patent/US20040254108A1/en
Priority claimed from TW92133577A external-priority patent/TW200427698A/en
Application filed by Oncomax Acquisition Corp, Jing Ma, Yajun Guo filed Critical Oncomax Acquisition Corp
Priority to CA002528595A priority Critical patent/CA2528595A1/en
Priority to AU2004252465A priority patent/AU2004252465A1/en
Priority to EP04776301A priority patent/EP1633398A4/en
Priority to JP2006533567A priority patent/JP2007515946A/en
Publication of WO2005001048A2 publication Critical patent/WO2005001048A2/en
Publication of WO2005001048A3 publication Critical patent/WO2005001048A3/en
Priority to IL172243A priority patent/IL172243A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Provided herein is a chimeric protein, which chimeric protein comprises a Flt3 ligand, or a biologically active fragment thereof, and a proteinuous or peptidyl tumoricidal agent, and uses thereof, particularly in the treatment of malignancy.
PCT/US2004/017765 2003-06-13 2004-06-04 Preparation and application of anti-tumor bifunctional fusion proteins WO2005001048A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002528595A CA2528595A1 (en) 2003-06-13 2004-06-04 Preparation and application of anti-tumor bifunctional fusion proteins
AU2004252465A AU2004252465A1 (en) 2003-06-13 2004-06-04 Preparation and application of anti-tumor bifunctional fusion proteins
EP04776301A EP1633398A4 (en) 2003-06-13 2004-06-04 Preparation and application of anti-tumor bifunctional fusion proteins
JP2006533567A JP2007515946A (en) 2003-06-13 2004-06-04 Preparation and application of anti-tumor dual function fusion protein
IL172243A IL172243A0 (en) 2003-06-13 2005-11-29 Preparation and application of anti-tumor bifunctional fusion proteins

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN03129290.9 2003-06-13
CN03129290 2003-06-13
CN 200310119930 CN1297567C (en) 2003-06-13 2003-11-25 Double functional fusion protein possessing antineoplastic functions, method for making same and use thereof
CN2003101199300 2003-11-25
US10/723,003 2003-11-26
US10/723,003 US20040254108A1 (en) 2003-06-13 2003-11-26 Preparation and application of anti-tumor bifunctional fusion proteins
TW092133577 2003-11-28
TW92133577A TW200427698A (en) 2003-06-13 2003-11-28 Preparation and application of anti-tumor bifunctional fusion proteins

Publications (2)

Publication Number Publication Date
WO2005001048A2 WO2005001048A2 (en) 2005-01-06
WO2005001048A3 true WO2005001048A3 (en) 2005-06-16

Family

ID=33556472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/017765 WO2005001048A2 (en) 2003-06-13 2004-06-04 Preparation and application of anti-tumor bifunctional fusion proteins

Country Status (5)

Country Link
EP (1) EP1633398A4 (en)
JP (1) JP2007515946A (en)
AU (1) AU2004252465A1 (en)
CA (1) CA2528595A1 (en)
WO (1) WO2005001048A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552167B2 (en) 2009-10-20 2013-10-08 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing
CN104558194B (en) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 A kind of anti-CD20-Flex bifunctional fusion proteins, preparation method and the usage
JP7295283B2 (en) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド FLT3L-FC fusion proteins and methods of use
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy
GB202013477D0 (en) 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1633398A4 *
VAN SPRIEL A.B. ET AL.: "Immunotherapeutic perspective for bispecific antibodies", vol. 21, no. 8, August 2000 (2000-08-01), pages 391 - 397, XP004215167 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Also Published As

Publication number Publication date
CA2528595A1 (en) 2005-01-06
JP2007515946A (en) 2007-06-21
EP1633398A4 (en) 2007-02-28
AU2004252465A1 (en) 2005-01-06
EP1633398A2 (en) 2006-03-15
WO2005001048A2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
AU2001257620A1 (en) Supplemental heart pump methods and systems for supplementing blood through the heart
WO2003074551A8 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
AU1516301A (en) Use of a milk protein hydrolysate in the treatment of diabetes
WO2003083041A3 (en) Cripto-specific antibodies
WO2002088170A3 (en) Cripto blocking antibodies and uses thereof
WO2003029420A3 (en) Apo-2 ligand variants and uses thereof
AU6058500A (en) Fusion protein and uses thereof
AUPR688101A0 (en) Protein domains and their ligands
MXPA03007323A (en) Artificial proteins with reduced immunogenicity.
WO2004001009A3 (en) Apo-2 ligand/trail variants and uses thereof
MXPA03008739A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours.
WO2006060021A3 (en) Bifunctional fusion proteins containing the flt3 ligand
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
IL206604A (en) Transmembrane protein, 24p4c12, expressed in prostate cancer, immunogenic compositions comprising them and uses thereof
IL153539A0 (en) Protein complexes and methods for the preparation thereof
WO2004069206A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
AU2002346530A1 (en) Breathable blood and viral barrier fabric
WO2005001048A3 (en) Preparation and application of anti-tumor bifunctional fusion proteins
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
AU2002233424A1 (en) Peptides having affinity for the GP120 viral protein and use thereof
AU2002364808A1 (en) Polynucleotide and protein involved in synaptogenesis, variants thereof, and their therapeutic and diagnostic uses
ZA200300777B (en) Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts.
AU2002252773A1 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
HUP0202270A3 (en) Antitumor antibodies, proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172243

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004776301

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2528595

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004252465

Country of ref document: AU

Ref document number: 2006533567

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2623/KOLNP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004252465

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004776301

Country of ref document: EP